Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:SLS 18 October 2025 - 2 January 2026

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.
23 December 2025
·
SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (NASDAQ: SLS) traded at $1.74 per share as of 09:13 UTC on December 8, 2025, following new Phase 2 data for its SLS009 drug in relapsed/refractory AML-MR. The study showed a 46% overall response rate in 35 patients, with no dose-limiting toxicities or treatment-related deaths reported. The company plans to expand trials to newly diagnosed high-risk AML in early 2026.
8 December 2025
··
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences shares closed at $2.14 on Oct. 17, up about 100% year-to-date, then surged another 38% after hours. BlackRock disclosed a 5.4% stake on Oct. 18, joining other major funds that increased holdings in Q2. Sellas’s lead AML drug passed a Phase 3 interim safety review, and its CDK9 inhibitor showed promising Phase 2 results. The company ended Q2 with $25 million cash and raised $23.6 million in September.
20 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

SELLAS Life Sciences (NASDAQ: SLS) shares doubled year-to-date in 2025, closing at $2.14 on Oct. 17 after a 38% after-hours jump and hitting a 52-week high of $2.27. BlackRock disclosed a 5.4% stake in the company. Interim Phase 3 trial results for SELLAS’s lead cancer drug showed median survival over 13.5 months in AML patients. Final trial data is expected by year-end 2025.
18 October 2025

Stock Market Today

  • Bitcoin Rises Above $70,800 as Oil Prices Dip Amid Middle East Tensions
    March 20, 2026, 3:52 AM EDT. Bitcoin (BTC) surged past $70,800 on Friday, buoyed by a nearly 2% drop in West Texas Intermediate (WTI) crude oil prices following multinational plans to stabilize oil supplies through the Strait of Hormuz. Other major cryptocurrencies like ether (ETH), XRP, and solana (SOL) recorded modest gains below 1%, trailing BTC's performance. The decline in oil prices comes amid continuing Middle East military tensions and potential easing of U.S. sanctions on Iranian oil tankers. Meanwhile, the S&P 500 fell below its 200-day moving average, reflecting rising risk aversion that could impact both equity and crypto markets. Market watchers highlight oil's support near $92 and caution that geopolitical risks and Federal Reserve policy uncertainties continue to create volatility.
Go toTop